



Compounding Quality Center of Excellence's New Outsourcing Facility

Quality Beyond the Quality Unit

Tuesday, August 25, 2026

Speaker Bios

Kevin Hansen, PharmD, MS, BCSCP
Senior Director, Pharmacy Compounding, Operations, and Technology Services,
Premier Inc



Kevin N. Hansen, PharmD, MS, BCSCP, is Senior Director of Pharmacy Compounding, Operations, and Technology Services at Premier Inc., where he leads national initiatives supporting health systems with 503A and 503B compounding strategy, supplier evaluation, contracting, and compliance with USP <797> and <800>. He is a board-certified sterile compounding pharmacist and serves as an expert volunteer on the United States Pharmacopeia Compounding Expert Committee. Dr.

Hansen also serves as adjunct faculty at the UNC Eshelman School of Pharmacy and completed his PGY1/PGY2/MS health-system pharmacy administration and leadership training at UNC Medical Center.



Jeff Hval, RPh
Chief Pharmaceutical Officer, S-T-A-Q Pharma

Jeff Hval, RPh, is a co-founder and Chief Pharmaceutical Officer of STAQ Pharma, a hospital-owned, FDA-registered 503B outsourcing facility with operations in Denver, Colorado, and Columbus, Ohio. He has more than 20 years of experience in sterile drug formulation and compounding, aseptic processing, and hospital and infusion pharmacy leadership. At STAQ, Jeff leads product development by collaborating with hospitals to understand their patient-care needs and translate them into ready-to-administer medications that help address drug shortages, support medication safety, and improve clinical workflows.

Spencer Malkin, DC
Chief Executive Officer, SKNV



Dr. Spencer J. Malkin is the founder, thought leader, and Chief Executive Officer of Sincerus Pharmaceuticals aka SKNV. Actively participating on both the provider and supplier side of healthcare for more than 25 years, Dr. Malkin is uniquely able to identify and capitalize on health-related market trends. As he focused his endeavors in the pharmaceutical arena, he acted on the need to change the prescribing paradigm, resulting in SKNV.

Dr. Malkin has spent his entire career in the life sciences. He successfully owned and operated Comprehensive Outpatient Rehabilitation Facilities. His experience there led him to a multi-state, multi-system joint venture with 47 hospitals to establish Vestibular Diagnostic and Treatment Facilities known as Balance Care LLC. Dr. Malkin's passion and drive steered him into the pharmaceutical realm. He focused his efforts on owning and operating retail and compounding pharmacies. Beginning in 2013, Dr. Malkin stewarded a total reorganization of Vividus, a Pharmacy Holding Company that he co-founded. He transitioned from this to FDA Registered 503B Outsourcing. Dr. Malkin is an inventor and holds multiple intellectual property patents in the health sciences arena.

Meghan Murphy
Senior Advisor, Office of Compounding Quality and Compliance, FDA

Meghan Murphy is currently a Senior Advisor in the Office of Compounding Quality and Compliance. She is the Director for Research, Strategy, and Engagement for the Compounding Quality Center of Excellence (COE). She leads and is responsible for day to day operations of the research and analysis, annual conference, strategic planning, and outreach efforts for the COE. She previously served as the Acting Associate Director for Risk Science, Intelligence, and Prioritization for the Office of Unapproved Drugs and Labeling Compliance, Center for Drug Evaluation and Research, in the U.S. Food and Drug Administration. Prior to that, Ms. Murphy was a Pharmacologist in the same organization and worked on addressing scientific and regulatory issues concerning marketed unapproved drugs and drugs compounded by pharmacists. She began her career at FDA as a member of the Department of Health and Human Services Emerging Leaders Program. Ms. Murphy obtained a Ph.D. in Pharmacology and an M.A. in Organic Chemistry from the University of North Carolina at Chapel Hill, and a B.S. in Biochemistry from the University of Maryland, Baltimore County.

Moderator

Susan C. Winckler, RPh, Esq. **CEO, Reagan-Udall Foundation for the FDA**



Susan C. Winckler, RPh, Esq., is CEO of the Reagan-Udall Foundation for the Food and Drug Administration. Prior to accepting the Foundation post, Ms. Winckler served as President of Leavitt Partners Solutions. As President and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advised corporate executives on policy and business matters. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, and other stakeholders with a neutral forum to address domestic and global issues. As Chief of Staff for the FDA (2007-2009), Winckler managed the

Commissioner's Office, served both Republican and Democratic commissioners as their senior-most staff adviser, analyzed complex policy challenges, and represented FDA with myriad government entities and external stakeholders. Her earlier career service included more than a decade at the American Pharmacists Association. Winckler earned a bachelor's degree from the University of Iowa College of Pharmacy and her law degree magna cum laude from Georgetown University Law Center. She is an APhA Fellow, served as an elected member of the United States Pharmacopeial Convention (USP) Board of Trustees (2015-2020, 2020-2025) and Chair of that Board from 2019 to mid-2025. In 2023, she received the Distinguished Alumni Award of the Food and Drug Administration Alumni Association and, separately, was awarded the Osterhaus Medal for Lifetime Achievement by the Univ. of Iowa College of Pharmacy.